The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2021 | Areas of unmet need in patients with mastocytosis
Tracy George, MD, The University of Utah, Salt Lake City, UT, talks on areas of unmet need for the diagnosis, classification, and treatment of mastocytosis, including optimizing therapeutic approaches in patients with co-existing hematological malignancies often seen in systemic mastocytosis. In indolent mastocytosis, Prof. George highlights the benefit of avapritinib in patients with KIT mutations and touches on the pediatric population who also represent an area of unmet need. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Tracy George, MD, has served as a consultant for Blueprint Medicines Corporation.
